Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer

Defining Venous Involvement in Borderline Resectable Pancreatic Cancer

(2010) Yun Shin Chun et al.   ANNALS OF SURGICAL ONCOLOGY

Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement

(2009) Ross A. Abrams et al.   ANNALS OF SURGICAL ONCOLOGY

Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement

(2009) Mark P. Callery et al.   ANNALS OF SURGICAL ONCOLOGY

Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma

(2009) H Akita et al.   ONCOGENE

Histopathological Response to Preoperative Chemoradiation for Resectable Pancreatic Adenocarcinoma

(2008) Romuald Le Scodan et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head

(2008) Gauri R. Varadhachary et al.   JOURNAL OF CLINICAL ONCOLOGY

Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head

(2008) Douglas B. Evans et al.   JOURNAL OF CLINICAL ONCOLOGY

Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease

(2008) Matthew H.G. Katz et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

(2008) Viviane Hess et al.   LANCET ONCOLOGY